Immunomodulators and advanced therapies for maintenance of remission in Crohn’s disease: systematic review and network meta-analysis
Vassiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Jane Radford, Gordon William Moran · 2026
Read Immunomodulators and advanced therapies for maintenance of remission in Crohn’s disease: systematic review and network meta-analysis by Vassiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Jane Radford, Gordon William Moran (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13408072.txt.
Description
Vassiliki Sinopoulou and co-authors compare, in 2026, every newer therapy for keeping Crohn's disease quiet. With immunomodulators and biologics multiplying, choosing maintenance treatment is genuinely hard. The team therefore network-meta-analysed 37 randomised trials with 7,415 participants. They graded certainty and ranked treatments on relapse, response loss, and safety.
Adalimumab probably prevents clinical relapse versus placebo with moderate certainty and a moderate effect. Its biosimilar cousin and infliximab may also prevent relapse, with the biosimilar posting the largest effect on loss of response. Upadacitinib and several other agents likely prevent response loss, each needing about two patients treated per success. Endoscopic relapse could not be analysed for lack of data. Safety evidence was imprecise, though treatments looked generally safe short-term. The rankings give clinicians a comparative map, not a verdict.
Catalog record
| CREATOR | Vassiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Jane Radford, Gordon William Moran |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |